Limits...
Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.

Ramos C, Napoleão P, Selas M, Freixo C, Viegas Crespo AM, Mota Carmo M, Cruz Ferreira R, Pinheiro T - Dis. Markers (2014)

Bottom Line: Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05).Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up.Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

View Article: PubMed Central - PubMed

Affiliation: Instituto de Biociências e Bioengenharia (IBB), Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais 1, 1049-001 Lisboa, Portugal ; Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, 1069-024 Lisboa, Portugal.

ABSTRACT
We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

Show MeSH

Related in: MedlinePlus

VEGF concentration in controls and in patients at admission, 1-month and 1-year after.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4109329&req=5

fig1: VEGF concentration in controls and in patients at admission, 1-month and 1-year after.

Mentions: Patients were reevaluated 1-month and 1-year after intervention. The VEGF concentration showed a positive evolution through time in 84% of patients. The longitudinal changes of VEGF concentrations in the serum of patients significantly increased to 1-month and remained relatively steady to 1-year approaching the VEGF levels of controls (Figure 1). The interaction of type of stent positioned in the model of VEGF changes over time significantly influenced the average changes of VEGF from baseline to 1-year. The number of drug eluting stents (DES) positioned was correlated with a decrease in the average changes of VEGF to 1-year (P = 0.05). Counteracting this trend, patients carrying bare metal stents (BMS) showed a more steep average change in VEGF increases to 1-year (P = 0.04).


Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.

Ramos C, Napoleão P, Selas M, Freixo C, Viegas Crespo AM, Mota Carmo M, Cruz Ferreira R, Pinheiro T - Dis. Markers (2014)

VEGF concentration in controls and in patients at admission, 1-month and 1-year after.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4109329&req=5

fig1: VEGF concentration in controls and in patients at admission, 1-month and 1-year after.
Mentions: Patients were reevaluated 1-month and 1-year after intervention. The VEGF concentration showed a positive evolution through time in 84% of patients. The longitudinal changes of VEGF concentrations in the serum of patients significantly increased to 1-month and remained relatively steady to 1-year approaching the VEGF levels of controls (Figure 1). The interaction of type of stent positioned in the model of VEGF changes over time significantly influenced the average changes of VEGF from baseline to 1-year. The number of drug eluting stents (DES) positioned was correlated with a decrease in the average changes of VEGF to 1-year (P = 0.05). Counteracting this trend, patients carrying bare metal stents (BMS) showed a more steep average change in VEGF increases to 1-year (P = 0.04).

Bottom Line: Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05).Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up.Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

View Article: PubMed Central - PubMed

Affiliation: Instituto de Biociências e Bioengenharia (IBB), Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais 1, 1049-001 Lisboa, Portugal ; Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, 1069-024 Lisboa, Portugal.

ABSTRACT
We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

Show MeSH
Related in: MedlinePlus